LEXINGTON, Mass., May 30, 2019 /PRNewswire/ -- Aldeyra
Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology
company devoted to developing and commercializing next-generation
medicines to improve the lives of patients with immune-mediated
diseases, today announced that Todd C.
Brady, M.D., Ph.D., President and CEO of Aldeyra, will
present at the Jefferies 2019 Global Healthcare Conference on
Friday, June 7, 2019 at 10:30 AM EDT at the Grand Hyatt in New York, NY.
The presentation will be webcast live and available for replay
on the investor relations page of the Aldeyra Therapeutics
corporate website at www.aldeyra.com.
About Aldeyra
Therapeutics
Aldeyra Therapeutics is a
biotechnology company devoted to developing and commercializing
next-generation medicines to improve the lives of patients with
immune-mediated diseases. Aldeyra's lead product candidate,
reproxalap, is a first-in-class treatment in late-stage development
for dry eye disease, allergic conjunctivitis, noninfectious
anterior uveitis, and Sjögren-Larsson Syndrome. The company is also
developing other product candidates for proliferative
vitreoretinopathy and other retinal diseases, post-transplant
lymphoproliferative disease, autoimmune disease, metabolic disease,
and cancer. None of Aldeyra's product candidates have been approved
for sale in the U.S. or elsewhere.
Corporate Contact:
David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcmullin@aldeyra.com
Investor Contact:
Chris Brinzey
Westwicke, an ICR Company
Tel: 339-970-2843
Chris.brinzey@westwicke.com
View original
content:http://www.prnewswire.com/news-releases/aldeyra-therapeutics-to-participate-in-the-jefferies-2019-global-healthcare-conference-300858733.html
SOURCE Aldeyra Therapeutics, Inc.